The knowledge accumulated over the past two decades has revealed that the natural history of metabolic dysfunction-associated steatotic liver disease (MASLD) and the drivers of the disease severity are not only complex but also exhibit variation among patients. This intricate clinical scenario entails major therapeutic and management implications. In this review, we provide a comprehensive examination of recent advancements in our understanding of MASLD heterogeneity, drawing insights from multiomics and panomics studies.
The discussion herein explores the instrumental role of panomics in MASLD research, elucidating the potential for the identification of molecular subtypes that exhibit divergent survival outcomes or heterogeneous responses to various treatments. Furthermore, we provide insights into the challenges in addressing disease heterogeneity and potential solutions. Finally, the most advanced technological advancements and prospective research directions in the domain of MASLD research are delineated, with the objective of facilitating the implementation of personalized diagnosis and interventions.
Background/Aims Evidence suggests that the gastrointestinal microbiome plays a significant role in the biology of metabolic dysfunction-associated steatotic liver disease (MASLD). However, it remains unclear whether disparities in the gut microbiome across intestinal tissular compartments between the sexes lead to MASLD pathogenesis.
Methods Sex-specific analyses of microbiome composition in two anatomically distinct regions of the gut, the small intestine and colon, were performed using an experimental model of MASLD. The study involved male and female spontaneously hypertensive rats and the Wistar-Kyoto control rat strain, which were fed either a standard chow diet or a high-fat diet for 12 weeks to induce MASLD (12 rats per group). High-throughput 16S sequencing was used for microbiome analysis.
Results There were significant differences in the overall microbiome composition of male and female rats with MASLD, including variations in topographical gut regions. The beta diversity of the jejunal and colon microbiomes was higher in female rats than in male rats (PERMANOVA p-value=0.001). Sex-specific analysis and discriminant features using LEfSe showed considerable variation in bacterial abundance, along with distinct functional properties, in the jejunum and colon of animals with MASLD. Significantly elevated levels of lipopolysaccharide and protein expression of Toll-like receptor 4 were observed in the livers of male rats with MASLD compared with their female counterparts.
Conclusions This study uncovered sexual dimorphism in the gut microbiome of MASLD and identified microbial heterogeneity within intestinal compartments. Insights into sex-specific variations in gut microbiome composition could facilitate customised treatment strategies.
Citations
Citations to this article as recorded by
MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women Ilaria Milani, Marianna Chinucci, Frida Leonetti, Danila Capoccia Biomedicines.2025; 13(4): 855. CrossRef
Characteristics of serum bile acid profiles among individuals with metabolic dysfunction-associated steatotic liver disease Sheng Lyu, Jiani Yang, Xin Xin, Qinmei Sun, Beiyu Cai, Xin Wang, Ziming An, Jian Sun, Yiyang Hu, Lei Shi, Qin Feng, Xiaojun Gou BMC Gastroenterology.2025;[Epub] CrossRef
Gut-Liver Axis: The Role of Intestinal Microbiota and Their Metabolites in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease Chao Cui, Shuai Gao, Jingfei Shi, Kai Wang Gut and Liver.2025; 19(4): 479. CrossRef
Triglyceride-glucose-waist circumference index: A powerful tool for metabolic dysfunction-associated steatotic liver disease Bryan Adrian Priego-Parra, Berenice M Román-Calleja, Rocio Gallego-Duran, Jordi Gracia-Sancho, Jose Antonio Velarde Ruiz-Velasco, Jose Maria Remes-Troche World Journal of Hepatology.2025;[Epub] CrossRef
Sex and gender differences in metabolic dysfunction-associated liver disease Rishitha Penmetsa, Sasha Kapil, Lisa B. VanWagner Indian Journal of Gastroenterology.2025;[Epub] CrossRef
Animal models of lean metabolic dysfunction-associated steatotic liver disease (MASLD): bridging pathogenesis and novel drug discovery Stavros P. Papadakos, Chara Georgiadou, Eva Kassi, Rallia-Iliana Velliou, Antonios Chatzigeorgiou Expert Opinion on Drug Discovery.2025; : 1. CrossRef
Early portal hypertension in metabolic dysfunction-associated steatotic liver disease: a concise review Iván López-Méndez, Eva Juárez-Hernández, Juan Pablo Soriano-Márquez, Misael Uribe, Graciela Castro-Narro Expert Review of Gastroenterology & Hepatology.2025; 19(7): 755. CrossRef
Correspondence on Editorial regarding “Identification of signature gene set as highly accurate determination of MASLD progression” Sungju Jung, Sumin Yoon, Jong Hoon Park, Yeon-Su Lee, Kyung Hyun Yoo Clinical and Molecular Hepatology.2024; 30(2): 287. CrossRef
The knowledge on the genetic component of non-alcoholic fatty liver disease (NAFLD) has grown exponentially over the last 10 to 15 years. This review summarizes the current evidence and the latest developments in the genetics of NAFLD and non-alcoholic steatohepatitis (NASH) from the immune system’s perspective. Activation of innate and or adaptive immune response is an essential driver of NAFLD disease severity and progression. Lipid and immune pathways are crucial in the pathophysiology of NAFLD and NASH. Here, we highlight novel applications of genomic techniques, including single-cell sequencing and the genetics of gene expression, to elucidate the potential involvement of NAFLD/NASH-risk alleles in modulating immune system cells. Together, our focus is to provide an overview of the potential involvement of the NAFLD/NASH-related risk variants in mediating the immune-driven liver disease severity and diverse systemic pleiotropic effects.
Citations
Citations to this article as recorded by
Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study Byungyoon Yun, Heejoo Park, Sang Hoon Ahn, Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon American Journal of Gastroenterology.2025; 120(2): 410. CrossRef
Unraveling Mechanisms of Genetic Risks in Metabolic Dysfunction–Associated Steatotic Liver Diseases: A Pathway to Precision Medicine Xiang Zhang, Kyong-Mi Chang, Jun Yu, Rohit Loomba
Annual Review of Pathology: Mechanisms of Disease
.2025; 20(1): 375. CrossRef
Examination of the causal role of immune cells in non-alcoholic fatty liver disease by a bidirectional Mendelian randomization study Yu Li, Xiaodan Lv, Jianing Lin, Shiquan Li, Guangfu Lin, Zhixi Huang, Deyi Chen, Lichun Han, Lingling Zhan, Xiaoping Lv Open Medicine.2025;[Epub] CrossRef
The correlation between the polymorphism of lysolecithin acyltransferase (MBOAT7) rs641738 and liver fibrosis Yuxia Yang, Xiang Chen, Huiqin Zhang, Gang Yang, Xiaoyun Zhu, Xiujing Si, Feilong Chen, Yan Zhao, Feng Jin, Juanjuan Lu Personalized Medicine.2025; 22(2): 113. CrossRef
Role of genetic variants and DNA methylation of lipid metabolism-related genes in metabolic dysfunction-associated steatotic liver disease Jun-Jie Wang, Xiao-Yuan Chen, Yi-Rong Zhang, Yan Shen, Meng-Lin Zhu, Jun Zhang, Jun-Jie Zhang Frontiers in Physiology.2025;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease, Recent Revision of Terminology and Its Implications Hyo Young Lee, Eileen L. Yoon The Korean Journal of Gastroenterology.2025; 85(2): 126. CrossRef
Unlocking the gut-liver axis: microbial contributions to the pathogenesis of metabolic-associated fatty liver disease Mykhailo Buchynskyi, Iryna Kamyshna, Iryna Halabitska, Pavlo Petakh, Oksana Kunduzova, Valentyn Oksenych, Oleksandr Kamyshnyi Frontiers in Microbiology.2025;[Epub] CrossRef
Innate immune memory in macrophage differentiation and cardiovascular diseases Yukiteru Nakayama, Katsuhito Fujiu Inflammation and Regeneration.2025;[Epub] CrossRef
The PNPLA3 I148M variant is associated with immune cell infiltration and advanced fibrosis in MASLD: a prospective genotype–phenotype study Jaejun Lee, Jung Hoon Cha, Hee Sun Cho, Keungmo Yang, Hyun Yang, Heechul Nam, Mi Young Byun, Seok Keun Cho, Jinsung Park, Hyuk Wan Ko, Seong Wook Yang, Pil Soo Sung, Si Hyun Bae Journal of Gastroenterology.2025; 60(10): 1284. CrossRef
Delineating unique MASH-endothelial cells in metabolic dysfunction-associated steatotic liver disease using single-cell lensing Lianyong Liu, Hong Du, Fengying Wu, Chenxi Li, Jiajun Chen, Xiaoying Zhang, Qingyun Zhu, Xiangqi Li Digestive and Liver Disease.2025; 57(10): 1974. CrossRef
Genetic Variation in Angiotensin II Type 1 Receptor Is Linked to Lipid Levels and Hepatic Steatosis in Alcohol-Associated Liver Disease, but Not to Cirrhosis or Hepatocellular Carcinoma Hans Dieter Nischalke, Franziska Schmalz, Janett Fischer, Christine Möller, Madlen Matz-Soja, Benjamin Krämer, Bettina Langhans, Jacob Nattermann, Thomas Berg, Christian P. Strassburg, Philipp Lutz Gastroenterology Insights.2024; 15(1): 19. CrossRef
Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants Fernando Bril, Srilaxmi Kalavalapalli, Romina Lomonaco, Reginald Frye, Eddison Godinez Leiva, Kenneth Cusi JHEP Reports.2024; 6(7): 101092. CrossRef
The gene expression signature of metabolic dysfunction- associated steatotic liver disease from a multiomics perspective Carlos Jose Pirola, Silvia Sookoian Clinical and Molecular Hepatology.2024; 30(2): 174. CrossRef
Genome-wide association study of metabolic dysfunction-associated fatty liver disease in a Korean population Young Lee, Eun Ju Cho, Eun Kyung Choe, Min-Sun Kwak, Jong In Yang, Seung-Won Oh, Jeong Yoon Yim, Goh Eun Chung Scientific Reports.2024;[Epub] CrossRef
Advances in our understanding of the molecular heterogeneity of fatty liver disease: toward informed treatment decision making Carlos J Pirola, Silvia Sookoian Expert Review of Gastroenterology & Hepatology.2023; 17(4): 317. CrossRef
The effects of moderate alcohol consumption on non-alcoholic fatty liver disease Hyunwoo Oh, Won Sohn, Yong Kyun Cho Clinical and Molecular Hepatology.2023; 29(Suppl): S261. CrossRef
Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology Eileen Laurel Yoon, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(2): 371. CrossRef
Innovative Therapeutic Approaches in Non-Alcoholic Fatty Liver Disease: When Knowing Your Patient Is Key Marta Alonso-Peña, Maria Del Barrio, Ana Peleteiro-Vigil, Carolina Jimenez-Gonzalez, Alvaro Santos-Laso, Maria Teresa Arias-Loste, Paula Iruzubieta, Javier Crespo International Journal of Molecular Sciences.2023; 24(13): 10718. CrossRef
New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut–Liver–Heart Crosstalk Keungmo Yang, Myeongjun Song Nutrients.2023; 15(18): 3970. CrossRef
Waiting for the changes after the adoption of steatotic liver disease Eileen L. Yoon, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(4): 844. CrossRef
Genetic polymorphisms of CYP2B6 is a risk of metabolic associated fatty liver disease in Chinese population Jingwei Zhang, Shijie Ma, Wei Zhou, Jing Feng, Yuwei Kang, Wei Yang, Heping Zhang, Fei Deng Toxicology and Applied Pharmacology.2023; 481: 116770. CrossRef
Hidden in the Fat: Unpacking the Metabolic Tango Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Syndrome Mariana Boulos, Rabia S. Mousa, Nizar Jeries, Elias Simaan, Klode Alam, Bulus Bulus, Nimer Assy International Journal of Molecular Sciences.2025; 26(7): 3448. CrossRef
Correspondence to editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C” Tom Ryu, Young Chang, Seung Up Kim, Jae Young Jang Clinical and Molecular Hepatology.2025; 31(2): e203. CrossRef
Single-cell eQTL analysis identifies genetic variation underlying metabolic dysfunction-associated steatohepatitis Sung Eun Hong, Seon Ju Mun, Young Joo Lee, Taekyeong Yoo, Kyung-Suk Suh, Keon Wook Kang, Myung Jin Son, Won Kim, Murim Choi Nature Genetics.2025; 57(7): 1638. CrossRef
Biomarker-Driven Optimization of Saponin Therapy in MASLD: From Mouse Models to Human Liver Organoids Hye Young Kim, Ju Hee Oh, Hyun Sung Kim, Dae Won Jun Antioxidants.2025; 14(8): 943. CrossRef
Non-invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring Gong Feng, Vincent Wai-Sun Wong, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng Gut.2025; 74(10): 1741. CrossRef
Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD) Raquel Benedé-Ubieto, Francisco Javier Cubero, Yulia A. Nevzorova Gut Microbes.2024;[Epub] CrossRef
Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice. Authors' reply Eunice X. X. Tan, Daniel Q. Huang, Mindie H. Nguyen Alimentary Pharmacology & Therapeutics.2024; 60(3): 411. CrossRef
Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update Silvia Sookoian, Yaron Rotman, Luca Valenti Clinical Gastroenterology and Hepatology.2024; 22(11): 2177. CrossRef
Ex Vivo Tools and Models in MASLD Research Rallia-Iliana Velliou, Eirini Giannousi, Christiana Ralliou, Eva Kassi, Antonios Chatzigeorgiou Cells.2024; 13(22): 1827. CrossRef
Advances in our understanding of the molecular heterogeneity of fatty liver disease: toward informed treatment decision making Carlos J Pirola, Silvia Sookoian Expert Review of Gastroenterology & Hepatology.2023; 17(4): 317. CrossRef
Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response Silvia Sookoian, Carlos J. Pirola Clinical and Molecular Hepatology.2023; 29(Suppl): S184. CrossRef
The effects of moderate alcohol consumption on non-alcoholic fatty liver disease Hyunwoo Oh, Won Sohn, Yong Kyun Cho Clinical and Molecular Hepatology.2023; 29(Suppl): S261. CrossRef
Despite more than two decades of extensive research focusing on nonalcoholic fatty liver disease (NAFLD), no approved therapy for steatohepatitis—the severe histological form of the disease—presently exists. More importantly, new drugs and small molecules with diverse molecular targets on the pathways of hepatocyte injury, inflammation, and fibrosis cannot achieve the primary efficacy endpoints. Precision medicine can potentially overcome this issue, as it is founded on extensive knowledge of the druggable genome/proteome. Hence, this review summarizes significant trends and developments in precision medicine with a particular focus on new potential therapeutic discoveries modeled via systems biology approaches. In addition, we computed and simulated the potential utility of the NAFLD polygenic risk score, which could be conceptually very advantageous not only for early disease detection but also for implementing actionable measures. Incomplete knowledge of the druggable NAFLD genome severely impedes the drug discovery process and limits the likelihood of identifying robust and safe drug candidates. Thus, we close this article with some insights into emerging disciplines, such as chemical genetics, that may accelerate accurate identification of the druggable NAFLD genome/proteome.
Citations
Citations to this article as recorded by
NAFLD No More: A Review of Current Guidelines in the Diagnosis and Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Kerim B. Kaylan, Sonali Paul Current Diabetes Reports.2025;[Epub] CrossRef
The Proteomics of MASLD Progression: Insights From Functional Analysis to Drive the Development of New Therapeutic Solutions Carlos José Pirola, Tomas Fernández Gianotti, Silvia Sookoian Alimentary Pharmacology & Therapeutics.2025; 61(4): 614. CrossRef
Statins as a Potential Treatment for Non-alcoholic Fatty Liver Disease: Target Deconvolution using Protein-protein Interaction Network Analysis Ali Mahmoudi, Alexandra E. Butler, Alexander N. Orekhov, Tannaz Jamialahmadi, Amirhossein Sahebkar Current Medicinal Chemistry.2025; 32(7): 1355. CrossRef
Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease Andrea Caddeo, Stefano Romeo Clinical and Molecular Hepatology.2025; 31(Suppl): S76. CrossRef
An association study of SERPINA1 gene polymorphisms with the risk of metabolic dysfunction-associated steatotic liver disease In an Iranian population: A preliminary case-control study Samira Abdollahi, Abbas Sahebghadam Lotfi, Ramin Saravani, Hamed Taheri Biochemistry and Biophysics Reports.2025; 42: 101974. CrossRef
Interplay of the pathophysiological mechanisms of non-alcoholic fatty liver disease, diabetes mellitus, and inflammation: A growing threat to public health Sharon Olabisoye Oladipupo, Emmanuel Henry Ezenabor, Adebola Busola Ojo, Akingbolabo Daniel Ogunlakin, Oluwafemi Adeleke Ojo Obesity Medicine.2025; 55: 100613. CrossRef
Repurposing daclatasvir for MASLD Therapy—A promising step forward with challenges ahead Carlos Jose Pirola Journal of Lipid Research.2025; 66(8): 100857. CrossRef
Development of a diagnostic model for MASLD and identification of daidzein as the potential drug using bioinformatics analysis and experiments Tao Wang, Hao Zhang, Kaixia Wang, Chunxue Liu, Nan Kong, Luocheng Zhou, Lihong Qu Frontiers in Immunology.2025;[Epub] CrossRef
The sulfur microbial diet and risk of nonalcoholic fatty liver disease: a prospective gene–diet study from the UK Biobank Zhening Liu, Hangkai Huang, Jiaqi Ruan, Zejun Wang, Chengfu Xu The American Journal of Clinical Nutrition.2024; 119(2): 417. CrossRef
Exploration of the Key Genes Involved in Non-alcoholic Fatty Liver Disease and Possible MicroRNA Therapeutic Targets Ali Mahmoudi, Amin Jalili, Alexandra E. Butler, Seyed H. Aghaee-Bakhtiari, Tannaz Jamialahmadi, Amirhossein Sahebkar Journal of Clinical and Experimental Hepatology.2024; 14(4): 101365. CrossRef
siRNA-mediated gene silencing for non-alcoholic fatty liver disease: A comprehensive review of molecular targets Ali Mahmoudi, Mehdi Rostami, Mohammad Mahdi Hajihasani, Vasily N. Sukhorukov, Prashant Kesharwani, Amirhossein Sahebkar European Polymer Journal.2024; 208: 112866. CrossRef
PARVB and HSD17B13 variants are associated with nonalcoholic fatty liver disease in children Kyung Jae Lee, Jin Soo Moon, Jin Gyu Lim, Homin Huh, Jeong Eun Ahn, Lia Kim, Nan Young Kim, Jae Sung Ko Journal of Gastroenterology and Hepatology.2024; 39(6): 1172. CrossRef
Analysis of the therapeutic potential of miR-124 and miR-16 in non-alcoholic fatty liver disease Ali Mahmoudi, Amin Jalili, Seyed Hamid Aghaee-Bakhtiari, Reza Kazemi Oskuee, Alexandra E. Butler, Manfredi Rizzo, Amirhossein Sahebkar Journal of Diabetes and its Complications.2024; 38(4): 108722. CrossRef
Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches Seyedeh Kosar Mahmoudi, Shadi Tarzemani, Taha Aghajanzadeh, Mohammadreza Kasravi, Behzad Hatami, Mohammad Reza Zali, Kaveh Baghaei European Journal of Medical Research.2024;[Epub] CrossRef
Shining a spotlight on sarcopenia and myosteatosis in liver disease and liver transplantation Sophie Reichelt, Uta Merle, Miriam Klauss, Christoph Kahlert, Georg Lurje, Arianeb Mehrabi, Zoltan Czigany Liver International.2024; 44(7): 1483. CrossRef
A Precision Medicine Guided Approach to the Utilization of Biomarkers in MASLD Nimish Thakral, Hailemichael Desalegn, Luis Antonio Diaz, Daniel Cabrera, Rohit Loomba, Marco Arrese, Juan Pablo Arab Seminars in Liver Disease.2024; 44(03): 273. CrossRef
Gut microbes, diet, and genetics as drivers of metabolic liver disease: a narrative review outlining implications for precision medicine Jake B. Hermanson, Samar A. Tolba, Evan A. Chrisler, Vanessa A. Leone The Journal of Nutritional Biochemistry.2024; 133: 109704. CrossRef
Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update Silvia Sookoian, Yaron Rotman, Luca Valenti Clinical Gastroenterology and Hepatology.2024; 22(11): 2177. CrossRef
Non-alcoholic fatty liver disease: the pathologist’s perspective Wei-Qiang Leow, Anthony Wing-Hung Chan, Paulo Giovanni L. Mendoza, Regina Lo, Kihan Yap, Haeryoung Kim Clinical and Molecular Hepatology.2023; 29(Suppl): S302. CrossRef
Non-alcoholic fatty liver disease: Definition and subtypes Seul Ki Han, Soon Koo Baik, Moon Young Kim Clinical and Molecular Hepatology.2023; 29(Suppl): S5. CrossRef
Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response Silvia Sookoian, Carlos J. Pirola Clinical and Molecular Hepatology.2023; 29(Suppl): S184. CrossRef
Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease Georg Semmler, Christian Datz, Michael Trauner Clinical and Molecular Hepatology.2023; 29(Suppl): S244. CrossRef
Advances in our understanding of the molecular heterogeneity of fatty liver disease: toward informed treatment decision making Carlos J Pirola, Silvia Sookoian Expert Review of Gastroenterology & Hepatology.2023; 17(4): 317. CrossRef
Identification of disease-related genes and construction of a gene co-expression database in non-alcoholic fatty liver disease Hua Ye, Mengxia Sun, Mingli Su, Dahua Chen, Huiwei Liu, Yanyan Ma, Wenjing Luo, Hong Li, Feng Xu Frontiers in Genetics.2023;[Epub] CrossRef
Examining genetic associations with hepatic steatosis in Mexican-origin adults Mario Jesus Trejo, Kristin E. Morrill, Yann C. Klimentidis, David O. Garcia Annals of Hepatology.2023; 28(5): 101120. CrossRef
Exploring the Role of Enhancer-Mediated Transcriptional Regulation in Precision Biology Xueyan Wang, Danli Liu, Jing Luo, Dashuai Kong, Yubo Zhang International Journal of Molecular Sciences.2023; 24(13): 10843. CrossRef
Associations of MAFLD and MAFLD subtypes with the risk of the incident myocardial infarction and stroke Shen Chen, Hongliang Xue, Rong Huang, Ke Chen, Haoyang Zhang, Xu Chen Diabetes & Metabolism.2023; 49(5): 101468. CrossRef
Serum metabolomic profiling unveils distinct sex-related metabolic patterns in NAFLD Charalambos Fotakis, Ioanna-Panagiota Kalafati, Athina I. Amanatidou, Vasiliki Andreou, Manolis Matzapetakis, Maria Kafyra, Iraklis Varlamis, Maria Zervou, George V. Dedoussis Frontiers in Endocrinology.2023;[Epub] CrossRef
Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease Chander K. Negi, Pavel Babica, Lola Bajard, Julie Bienertova-Vasku, Giovanni Tarantino Metabolism.2022; 126: 154925. CrossRef
Effects of PNPLA3, TM6SF2 and SAMM50 on the development and severity of non‐alcoholic fatty liver disease in children Kyung Jae Lee, Jin Soo Moon, Nan Young Kim, Jae Sung Ko Pediatric Obesity.2022;[Epub] CrossRef
Metabolic dysfunction-associated fatty liver disease: advances in genetic and epigenetic implications Carlos J. Pirola, Silvia Sookoian Current Opinion in Lipidology.2022; 33(2): 95. CrossRef
Investigation of the Effect of Curcumin on Protein Targets in NAFLD Using Bioinformatic Analysis Ali Mahmoudi, Alexandra E. Butler, Muhammed Majeed, Maciej Banach, Amirhossein Sahebkar Nutrients.2022; 14(7): 1331. CrossRef
TissueSpace: a web tool for rank-based transcriptome representation and its applications in molecular medicine Yiruo He, Wei Liu Genes & Genomics.2022; 44(7): 793. CrossRef
Intrahepatic inflammatory IgA+PD-L1high monocytes in hepatocellular carcinoma development and immunotherapy Pil Soo Sung, Dong Jun Park, Pu Reun Roh, Kyoung Do Mun, Sung Woo Cho, Gil Won Lee, Eun Sun Jung, Sung Hak Lee, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Jonghwan Choi, Jaegyoon Ahn, Seung Kew Yoon Journal for ImmunoTherapy of Cancer.2022; 10(5): e003618. CrossRef
Precision medicine in nonalcoholic fatty liver disease Amedeo Lonardo Journal of Gastroenterology and Hepatology.2022; 37(7): 1175. CrossRef
Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update Nicholas W. S. Chew, Cheng Han Ng, Emily Truong, Mazen Noureddin, Kris V. Kowdley Seminars in Liver Disease.2022; 42(03): 379. CrossRef
Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD Beom Kyung Kim, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Tuo Lin, Xin M. Tu, Jaclyn Bergstrom, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi N Journal of Hepatology.2022; 77(6): 1482. CrossRef
Personalized medicine in nonalcoholic fatty liver disease Carlos J. Pirola, Silvia Sookoian Clinical and Molecular Hepatology.2022; 28(4): 935. CrossRef
Pleiotropy within gene variants associated with nonalcoholic fatty liver disease and traits of the hematopoietic system Carlos Jose Pirola, Adrian Salatino, Silvia Sookoian World Journal of Gastroenterology.2021; 27(4): 305. CrossRef
The lipidome in nonalcoholic fatty liver disease: actionable targets Carlos J. Pirola, Silvia Sookoian Journal of Lipid Research.2021; 62: 100073. CrossRef
Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity Marco Arrese, Juan P. Arab, Francisco Barrera, Benedikt Kaufmann, Luca Valenti, Ariel E. Feldstein Seminars in Liver Disease.2021; 41(04): 421. CrossRef
From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple? Seong Hee Kang, Yuri Cho, Soung Won Jeong, Seung Up Kim, Jin-Woo Lee Clinical and Molecular Hepatology.2021; 27(2): 257. CrossRef
Body weight variability and the risk of cardiovascular outcomes in patients with nonalcoholic fatty liver disease Mi Na Kim, Kyungdo Han, Juhwan Yoo, Yeonjung Ha, Young Eun Chon, Ju Ho Lee, Tracey G. Simon, Andrew T. Chan, Seong Gyu Hwang Scientific Reports.2021;[Epub] CrossRef
Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management Amedeo Lonardo, Juan Pablo Arab, Marco Arrese Advances in Therapy.2021; 38(5): 2130. CrossRef
Genetic risk scores and personalization of care in fatty liver disease Cristiana Bianco, Federica Tavaglione, Stefano Romeo, Luca Valenti Current Opinion in Pharmacology.2021; 61: 6. CrossRef
NAFLD and Cardiometabolic Risk Factors: The Liver Fibrosis Trajectory Through the Lens of Biological Interactions Carlos J. Pirola, Silvia Sookoian Hepatology.2021; 73(2): 479. CrossRef
Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis Ali Mahmoudi, Alexandra E. Butler, Tannaz Jamialahmadi, Amirhossein Sahebkar, Bing Niu BioMed Research International.2021;[Epub] CrossRef
Editorial on Prevalence, Diagnosis and Treatment with 3 Different Statins of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role? Emir Muzurović, Brigita Smolović, Snežana Vujošević, Milan Petakov Current Vascular Pharmacology.2021; 19(5): 582. CrossRef
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease whose prevalence has reached global epidemic proportions. Although the disease is relatively benign in the early stages, when severe clinical forms, including nonalcoholic steatohepatitis (NASH), cirrhosis and even hepatocellular carcinoma, occur, they result in worsening the long-term prognosis. A growing body of evidence indicates that NAFLD develops from a complex process in which many factors, including genetic susceptibility and environmental insults, are involved. In this review, we focused on the genetic component of NAFLD, with special emphasis on the role of genetics in the disease pathogenesis and natural history. Insights into the topic of the genetic susceptibility in lean individuals with NAFLD and the potential use of genetic tests in identifying individuals at risk are also discussed.
Citations
Citations to this article as recorded by
Global Epidemiological Impact of PNPLA3 I148M on Liver Disease Julia Kozlitina, Silvia Sookoian Liver International.2025;[Epub] CrossRef
Statin‐associated regulation of hepatic PNPLA3 in patients without known liver disease Osman Ahmed, Vladimir S. Shavva, Laura Tarnawski, Wanmin Dai, Filip Borg, Viggo V. Olofsson, Ting Liu, Peter Saliba‐Gustafsson, Christian Simini, Matteo Pedrelli, Otto Bergman, Giuseppe Danilo Norata, Paolo Parini, Anders Franco‐Cereceda, Per Eriksson, St Journal of Internal Medicine.2025; 297(1): 47. CrossRef
Newly identified single-nucleotide polymorphism associated with the transition from nonalcoholic fatty liver disease to liver fibrosis: results from a nested case-control study in the UK biobank Yitong Ling, Yu Xuan Yang, Yan Chun Chen, Jing Hao Wang, Dong Ge Feng, Shi Jian Xiang, Xiaoyu Zhang, Jun Lyu, Sha Sha Li Annals of Medicine.2025;[Epub] CrossRef
Genome-wide association study of the fatty liver index in the Taiwanese population reveals shared and population-specific genetic risk factors across ethnicities Pei Pei Lau, Chun-Yu Wei, Min-Rou Lin, Wan-Hsuan Chou, Yu-Jui Yvonne Wan, Wei-Chiao Chang Cell & Bioscience.2025;[Epub] CrossRef
Fishing for Solutions: How Pre‐Conceptional Fish Oil Supplementation in Obese Fathers Reduces Risk of Non‐Alcoholic Fatty Liver Disease in Offspring Mice Junhui Yang, Akriti Shrestha, Latha Ramalingam Molecular Nutrition & Food Research.2025;[Epub] CrossRef
Genetic and metabolic characterization of individual differences in liver fat accumulation in Atlantic salmon Siri S. Horn, Anna K. Sonesson, Aleksei Krasnov, Muhammad L. Aslam, Borghild Hillestad, Bente Ruyter Frontiers in Genetics.2025;[Epub] CrossRef
Urinary biomarkers of drinking water disinfection byproducts in relation to blood-based liver function parameters among reproductive-aged Chinese women Ping-Ping Gui, Yan-Ling Deng, Min Zhang, Yu Miao, Peng-Hui Liu, Jia-Yue Zeng, Yang Wu, Cheng-Ru Li, Xiao-Ying Liu, Yang-Juan Li, Jin-Qin Zhu, A-Xue Liu, Bin Zhou, Fei Yang, Qiang Zeng Science of The Total Environment.2025; 970: 179016. CrossRef
The correlation between the polymorphism of lysolecithin acyltransferase (MBOAT7) rs641738 and liver fibrosis Yuxia Yang, Xiang Chen, Huiqin Zhang, Gang Yang, Xiaoyun Zhu, Xiujing Si, Feilong Chen, Yan Zhao, Feng Jin, Juanjuan Lu Personalized Medicine.2025; 22(2): 113. CrossRef
Weight loss in MASLD restores the balance of liver fatty acid sources Jennifer E. Lambert, Maria A. Ramos-Roman, Maressa J. Valdez, Jeffrey D. Browning, Thomas Rogers, Elizabeth J. Parks Journal of Clinical Investigation.2025;[Epub] CrossRef
Ppp1r3b
is a metabolic switch that shifts hepatic energy storage from lipid to glycogen
Kate Townsend Creasy, Minal B. Mehta, Carolin V. Schneider, Joseph Park, David Zhang, Swapnil V. Shewale, John S. Millar, Marijana Vujkovic, Nicholas J. Hand, Paul M. Titchenell, Joseph A. Baur, Daniel J. Rader Science Advances.2025;[Epub] CrossRef
Parental liver disease mortality is associated with unfavorable outcomes in patients with alcohol-associated hepatitis Wanzhu Tu, Samer Gawrieh, Lauren Nephew, Craig McClain, Qing Tang, Srinivasan Dasarathy, Vatsalya Vatsalya, Douglas A. Simonetto, Carla Kettler, Gyongyi Szabo, Bruce Barton, Yunpeng Yu, Patrick S. Kamath, Arun J. Sanyal, Laura Nagy, Mack C. Mitchell, Suth Hepatology Communications.2025;[Epub] CrossRef
Steatotic Liver Disease in Older Adults: Clinical Implications and Unmet Needs Daniel Clayton-Chubb, William W. Kemp, Ammar Majeed, Peter W. Lange, Jessica A. Fitzpatrick, Karl Vaz, John S. Lubel, Alexander D. Hodge, Joanne Ryan, John J. McNeil, Alice J. Owen, Robyn L. Woods, Stuart K. Roberts Nutrients.2025; 17(13): 2189. CrossRef
Sex Differences in the Association Between the Korean Healthy Eating Index and Liver Enzymes Among Korean Adults Seong-Uk Baek, Jin-Ha Yoon Nutrients.2025; 17(14): 2372. CrossRef
Genetic variants underlying precancerous conditions of hepatocellular carcinoma Jonathan Jaime G. Guerrero, Paolo C. Encarnacion, Mark Angelo S. del Rosario, Matthew Aldren S. Ora, Jiayan Zhou, Kin Israel Notarte, Wan‐Chun Li, Ching‐Wen Chang International Journal of Cancer.2025;[Epub] CrossRef
Genetic Variants, Metabolic Dysfunction-Associated Fatty Liver Disease, and Major Health Outcomes in Older Adults Daniel Clayton-Chubb, Ammar Majeed, William W. Kemp, Chenglong Yu, Peter W. Lange, Jessica A. Fitzpatrick, Robyn L. Woods, Andrew M. Tonkin, Andrew T. Chan, Mark R. Nelson, Joanne Ryan, Alexander D. Hodge, John S. Lubel, Hans G. Schneider, John J. McNeil, Biomedicines.2025; 13(8): 1977. CrossRef
Genetic determinants of hepatocellular carcinoma: role of PNPLA3, FABP2, FADS1/FADS2 genes in Yakuts Nadezhda I. Pavlova, Alexey V. Krylov, Alexey A. Bochurov, Ivan P. Troev, Khariton A. Kurtanov Russian Journal of Oncology.2025; 30(2): 114. CrossRef
Increased 1-deoxysphingolipids caused by an altered plasma alanine to serine ratio are associated with metabolic dysfunction-associated steatotic liver disease (MASLD) F. Wipfli, M. A. Lone, A. von Eckardstein, A. Verrijken, S. Francque, J. Weyler, L. Van Gaal, B. Staels, T. Hornemann Metabolomics.2025;[Epub] CrossRef
Heavy Metals, Gut Microbiota, and Biochemical Markers: Unraveling the Complexities of Obesity Ahmed Basim Mohamed Alamer, Majid Komijani, Shahnaz Shahrjerdi MicrobiologyOpen.2025;[Epub] CrossRef
From “MAFLD” to “MASLD”: Was This Revolution Worth It? A Head-to-Head Comparison of MAFLD and MASLD Criteria in Estimating Liver Disease Progression and Cardiovascular Risk in Real Life Marcello Dallio, Mario Romeo, Fiammetta Di Nardo, Carmine Napolitano, Paolo Vaia, Claudio Basile, Annachiara Coppola, Alessia Silvestrin, Giusy Senese, Marco Niosi, Alessandro Federico Livers.2025; 5(4): 58. CrossRef
A PNPLA3 gén rs738409 variánsának jelentősége metabolikus diszfunkcióhoz társult steatoticus májbetegségben Ákos Nádasdi, Gábor Firneisz Orvosi Hetilap.2025; 166(47): 1843. CrossRef
Navigating nonalcoholic fatty liver disease (NAFLD): Exploring the roles of estrogens, pharmacological and medical interventions, and life style Qianying Zuo, Nicole Hwajin Park, Jenna Kathryn Lee, Ashlie Santaliz-Casiano, Zeynep Madak-Erdogan Steroids.2024; 203: 109330. CrossRef
Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies Maurizio Parola, Massimo Pinzani Molecular Aspects of Medicine.2024; 95: 101231. CrossRef
The pathophysiology of MASLD: an immunometabolic perspective Julian Schwärzler, Felix Grabherr, Christoph Grander, Timon E. Adolph, Herbert Tilg Expert Review of Clinical Immunology.2024; 20(4): 375. CrossRef
Whole-Exome Sequencing (WES) Reveals Novel Sex-Specific Gene Variants in Non-Alcoholic Steatohepatitis (MASH) Jing Wei, Boyang Jason Wu, Sayed S. Daoud Genes.2024; 15(3): 357. CrossRef
Genetic and Metabolic Characteristics of Lean Nonalcoholic Fatty Liver Disease in a Korean Health Examinee Cohort Huiyul Park, Eileen L. Yoon, Goh Eun Chung, Eun Kyung Choe, Jung Ho Bae, Seung Ho Choi, Mimi Kim, Woochang Hwang, Hye-Lin Kim, Sun Young Yang, Dae Won Jun Gut and Liver.2024; 18(2): 316. CrossRef
Relevance of PNPLA3, TM6SF2, HSD17B13, and GCKR Variants to MASLD Severity in an Egyptian Population Nehal Elmansoury, Ahmed A. Megahed, Ahmed Kamal, Nefertiti El-Nikhely, Marina Labane, Manal Abdelmageed, Ann K. Daly, Ahmed Wahid Genes.2024; 15(4): 455. CrossRef
Probiotics—A Promising Novel Therapeutic Approach in the Management of Chronic Liver Diseases Gokulapriya Ramachandran, Biju Pottakkat Journal of Medicinal Food.2024; 27(6): 467. CrossRef
Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases Maja Thiele, Ida Falk Villesen, Lili Niu, Stine Johansen, Karolina Sulek, Suguru Nishijima, Lore Van Espen, Marisa Keller, Mads Israelsen, Tommi Suvitaival, Andressa de Zawadzki, Helene Bæk Juel, Maximilian Joseph Brol, Sara Elizabeth Stinson, Yun Huang, Journal of Hepatology.2024; 81(2): 345. CrossRef
The Relationship between Pathogenesis and Possible Treatments for the MASLD-Cirrhosis Spectrum Paulina Vidal-Cevallos, Adriana P. Sorroza-Martínez, Norberto C. Chávez-Tapia, Misael Uribe, Eduardo E. Montalvo-Javé, Natalia Nuño-Lámbarri International Journal of Molecular Sciences.2024; 25(8): 4397. CrossRef
Discovery of genomic loci for liver health and steatosis reveals overlap with glutathione redox genetics Rebecca L. Koch, James B. Stanton, Susan McClatchy, Gary A. Churchill, Steven W. Craig, Darian N. Williams, Mallory E. Johns, Kylah R. Chase, Dana L. Thiesfeldt, Jessica C. Flynt, Robert Pazdro Redox Biology.2024; 75: 103248. CrossRef
Human iPSC-derived liver co-culture spheroids to model liver fibrosis Laura Cools, Mina Kazemzadeh Dastjerd, Ayla Smout, Vincent Merens, Yuwei Yang, Hendrik Reynaert, Nouredin Messaoudi, Vincent De Smet, Manoj Kumar, Stefaan Verhulst, Catherine Verfaillie, Leo A van Grunsven Biofabrication.2024; 16(3): 035032. CrossRef
Role of the type 3 cytokines IL-17 and IL-22 in modulating metabolic dysfunction-associated steatotic liver disease Mohamed N. Abdelnabi, Ghada S. Hassan, Naglaa H. Shoukry Frontiers in Immunology.2024;[Epub] CrossRef
Global Prevalence of Nonalcoholic Fatty Liver Disease: An Updated Review Meta-Analysis comprising a Population of 78 million from 38 Countries Ehsan Amini-Salehi, Negin Letafatkar, Naeim Norouzi, Farahnaz Joukar, Arman Habibi, Mona Javid, Nazila Sattari, Mehrdad Khorasani, Ali Farahmand, Shervin Tavakoli, Behnaz Masoumzadeh, Elaheh Abbaspour, Sahand Karimzad, Amir Ghadiri, Gautam Maddineni, Moha Archives of Medical Research.2024; 55(6): 103043. CrossRef
The role of gut microbiota augmentation in managing non-alcoholic fatty liver disease: an in-depth umbrella review of meta-analyses with grade assessment Gautam Maddineni, Sri J. Obulareddy, Ruchir D. Paladiya, Rohan R. Korsapati, Shika Jain, Herby Jeanty, Fnu Vikash, Nayanika C. Tummala, Samatha Shetty, Arezoo Ghazalgoo, Abinash Mahapatro, Viswanadh Polana, Dhruvan Patel Annals of Medicine & Surgery.2024; 86(8): 4714. CrossRef
Advances in our understanding of the molecular heterogeneity of fatty liver disease: towards informed treatment decision making Carlos J Pirola, Silvia Sookoian Expert Review of Gastroenterology & Hepatology.2023;[Epub] CrossRef
Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response Silvia Sookoian, Carlos J. Pirola Clinical and Molecular Hepatology.2023; 29(Suppl): S184. CrossRef
The association of non‐alcoholic fatty liver disease between parents and adolescent children Yewan Park, Dong Hyun Sinn, Kyunga Kim, Geum‐Youn Gwak Alimentary Pharmacology & Therapeutics.2023; 57(2): 245. CrossRef
NAFLD and nutraceuticals: a review of completed phase III and IV clinical trials Omar E. Hegazi, Samer O. Alalalmeh, Ghala Rashid Humaid Alnuaimi, Moyad Shahwan, Ammar Abdulrahman Jairoun, Nasser M. Alorfi, Shaker A. Majrashi, Mustfa Faisal Alkhanani, Abdullah Alkhattabi, Mansour M. Alourfi, Faris A. Alsolami, Saeed Alsharif, Hatim Al Frontiers in Medicine.2023;[Epub] CrossRef
Using epigenomics to understand cellular responses to environmental influences in diseases Julia J. Wattacheril, Srilakshmi Raj, David A. Knowles, John M. Greally, Gregory P. Copenhaver PLOS Genetics.2023; 19(1): e1010567. CrossRef
Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives Daniel Clayton-Chubb, William Kemp, Ammar Majeed, John S. Lubel, Alex Hodge, Stuart K. Roberts Nutrients.2023; 15(3): 687. CrossRef
Lack of GPR180 ameliorates hepatic lipid depot via downregulation of mTORC1 signaling Ken Yoshida, Kazuha Yokota, Kazuhisa Watanabe, Hidetoshi Tsuda, Ayumi Matsumoto, Hiroaki Mizukami, Sadahiko Iwamoto Scientific Reports.2023;[Epub] CrossRef
TM6SF2-rs58542926 Genetic Variant Modifies the Protective Effect of a “Prudent” Dietary Pattern on Serum Triglyceride Levels Ioanna Panagiota Kalafati, Maria Dimitriou, Konstantinos Revenas, Alexander Kokkinos, Panos Deloukas, George V. Dedoussis Nutrients.2023; 15(5): 1112. CrossRef
Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation Neda Yahoo, Michael Dudek, Percy Knolle, Mathias Heikenwälder Journal of Hepatology.2023; 79(2): 538. CrossRef
Genetic Markers Predisposing to Nonalcoholic Steatohepatitis Aalam Sohal, Hunza Chaudhry, Kris V. Kowdley Clinics in Liver Disease.2023; 27(2): 333. CrossRef
The potential of integrating human and mouse discovery platforms to advance our understanding of cardiometabolic diseases Aaron W Jurrjens, Marcus M Seldin, Corey Giles, Peter J Meikle, Brian G Drew, Anna C Calkin eLife.2023;[Epub] CrossRef
Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons Michael H. Le, David M. Le, Thomas C. Baez, Yuankai Wu, Takanori Ito, Eunice Y. Lee, KeeSeok Lee, Christopher D. Stave, Linda Henry, Scott D. Barnett, Ramsey Cheung, Mindie H. Nguyen Journal of Hepatology.2023; 79(2): 287. CrossRef
Diversitätsfaktoren in der Gastroenterologie Teresa Hof, Robert Thimme, Peter Hasselblatt DMW - Deutsche Medizinische Wochenschrift.2023; 148(09): 519. CrossRef
A Review of the Effects of Fucoxanthin on NAFLD Nor Hafiza Sayuti, Khairul Najmi Muhammad Nawawi, Jo Aan Goon, Norfilza Mohd Mokhtar, Suzana Makpol, Jen Kit Tan Nutrients.2023; 15(8): 1954. CrossRef
Blood lactate levels are associated with an increased risk of metabolic dysfunction-associated fatty liver disease in type 2 diabetes: a real-world study Yi-Lin Ma, Jiang-Feng Ke, Jun-Wei Wang, Yu-Jie Wang, Man-Rong Xu, Lian-Xi Li Frontiers in Endocrinology.2023;[Epub] CrossRef
High fat in blood and body and increased risk of clinically diagnosed non-alcoholic fatty liver disease in 105,981 individuals Lærke Kristine Kyhl, Børge Grønne Nordestgaard, Anne Tybjærg-Hansen, Sune Fallgaard Nielsen Atherosclerosis.2023; 376: 1. CrossRef
Cross-tissue omics analysis discovers ten adipose genes encoding secreted proteins in obesity-related non-alcoholic fatty liver disease Nicholas Darci-Maher, Marcus Alvarez, Uma Thanigai Arasu, Ilakya Selvarajan, Seung Hyuk T. Lee, David Z. Pan, Zong Miao, Sankha Subhra Das, Dorota Kaminska, Tiit Örd, Jihane N. Benhammou, Martin Wabitsch, Joseph R. Pisegna, Ville Männistö, Kirsi H. Pietil eBioMedicine.2023; 92: 104620. CrossRef
Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, and Metabolic Repercussions: The Vicious Cycle and Its Interplay with Inflammation Rafał Frankowski, Mateusz Kobierecki, Andrzej Wittczak, Monika Różycka-Kosmalska, Tadeusz Pietras, Kasper Sipowicz, Marcin Kosmalski International Journal of Molecular Sciences.2023; 24(11): 9677. CrossRef
Effects of gut microbial therapy on lipid profile in individuals with non-alcoholic fatty liver disease: an umbrella meta-analysis study Amirhossein Naghipour, Ehsan Amini-Salehi, Mahdi Orang Gorabzarmakhi, Milad Shahdkar, Bahman Fouladi, Iraj Alipourfard, Zahra Momayez Sanat Systematic Reviews.2023;[Epub] CrossRef
Prospects of evolution-based artificial intelligence models in genome-wide studies to stratify genetic risk variants in nonalcoholic fatty liver disease Helen Huang, Wireko A. Awuah, Tulika Garg, Jyi Cheng Ng, Aashna Mehta, Krishna Ramamoorthy, Jacob Kalmanovich, Mohammad M. Hasan Annals of Medicine & Surgery.2023; 85(6): 2743. CrossRef
Genetic and metabolic aspects of non-alcoholic fatty liver disease (NAFLD) pathogenicity Saumya Madushani Samarasinghe, Asanka Sudeshini Hewage, Rohan Chaminda Siriwardana, Kamani Hemamala Tennekoon, Madunil Anuk Niriella, Sumadee De Silva Egyptian Journal of Medical Human Genetics.2023;[Epub] CrossRef
Role of Matrix Gla Protein in Transforming Growth Factor-β Signaling and Nonalcoholic Steatohepatitis in Mice Simon T. Hui, Lili Gong, Chantle Swichkow, Montgomery Blencowe, Dorota Kaminska, Graciel Diamante, Calvin Pan, Meet Dalsania, Samuel W. French, Clara E. Magyar, Päivi Pajukanta, Jussi Pihlajamäki, Kristina I. Boström, Xia Yang, Aldons J. Lusis Cellular and Molecular Gastroenterology and Hepatology.2023; 16(6): 943. CrossRef
Usefulness of PNPLA3 variant for predicting hepatic events in steatotic liver disease: a matter of ethnicity or baseline risk? Umberto Vespasiani‐Gentilucci, Luca Valenti, Stefano Romeo Liver International.2023; 43(10): 2052. CrossRef
New horizons of human genetics in digestive diseases Lanlan Chen, Guoyue Lv eGastroenterology.2023; 1(2): e100029. CrossRef
Microbiome and Genetic Factors in the Pathogenesis of Liver Diseases Dimitrina Miteva, Monika Peshevska-Sekulovska, Violeta Snegarova, Milena Peruhova, Georgi H. Vasilev, Georgi V. Vasilev, Metodija Sekulovski, Snezhina Lazova, Milena Gulinac, Latchezar Tomov, Antoaneta Mihova, Tsvetelina Velikova Gastroenterology Insights.2023; 14(4): 575. CrossRef
Prevalence of Nonalcoholic Fatty Liver Disease in Hypothyroid Subjects: A Cross-sectional Comparative Study Maharshi Patel, Sourya Acharya, Sunil Kumar Indian Journal of Medical Specialities.2023; 14(3): 145. CrossRef
Epigenetics factors in nonalcoholic fatty liver disease Carlos Jose Pirola, Silvia Sookoian Expert Review of Gastroenterology & Hepatology.2022; 16(6): 521. CrossRef
Effects of PNPLA3, TM6SF2 and SAMM50 on the development and severity of non‐alcoholic fatty liver disease in children Kyung Jae Lee, Jin Soo Moon, Nan Young Kim, Jae Sung Ko Pediatric Obesity.2022;[Epub] CrossRef
A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores Antonio De Vincentis, Federica Tavaglione, Oveis Jamialahmadi, Antonio Picardi, Raffaele Antonelli Incalzi, Luca Valenti, Stefano Romeo, Umberto Vespasiani-Gentilucci Clinical Gastroenterology and Hepatology.2022; 20(3): 658. CrossRef
Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank Antonio De Vincentis, Federica Tavaglione, Rocco Spagnuolo, Roberta Pujia, Dario Tuccinardi, Gianluca Mascianà, Antonio Picardi, Raffaele Antonelli Incalzi, Luca Valenti, Stefano Romeo, Umberto Vespasiani-Gentilucci International Journal of Obesity.2022; 46(3): 486. CrossRef
Genome‐Wide Association Study of NAFLD Using Electronic Health Records Cameron J. Fairfield, Thomas M. Drake, Riinu Pius, Andrew D. Bretherick, Archie Campbell, David W. Clark, Jonathan A. Fallowfield, Caroline Hayward, Neil C. Henderson, Peter K. Joshi, Nicholas L. Mills, David J. Porteous, Prakash Ramachandran, Robert K. S Hepatology Communications.2022; 6(2): 297. CrossRef
Prevalence and Predictors of Nonalcoholic Fatty Liver Disease in Family Members of Patients With Nonalcoholic Fatty Liver Disease Abhinav Anand, Amit A. Singh, Anshuman Elhence, Manas Vaishnav, Sagnik Biswas, Deepak Gunjan, Shivanand R. Gamanagatti, Baibaswata Nayak, Ramesh Kumar, Shalimar Journal of Clinical and Experimental Hepatology.2022; 12(2): 362. CrossRef
Association of UCP3 Polymorphisms with Nonalcoholic Steatohepatitis and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease Brazilian Patients Karla Sawada Toda-Oti, José Tadeu Stefano, Ana Mercedes Cavaleiro, Flair José Carrilho, Maria Lúcia Correa-Gianella, Cláudia Pinto Marques de Souza de Oliveira Metabolic Syndrome and Related Disorders.2022; 20(2): 114. CrossRef
Metabolism and Health Effects of Rare Sugars in a CACO-2/HepG2 Coculture Model Amar van Laar, Charlotte Grootaert, Filip Van Nieuwerburgh, Dieter Deforce, Tom Desmet, Koen Beerens, John Van Camp Nutrients.2022; 14(3): 611. CrossRef
Early Diagnosis of Non-Alcoholic Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease 露文 李 Advances in Clinical Medicine.2022; 12(02): 986. CrossRef
Epidemiological and Genetic Aspects of NAFLD and NASH in Mexico Paulina Vidal‐Cevallos, Aldo Torre, Nahum Mendez‐Sanchez, Misael Uribe, Norberto C. Chavez‐Tapia Clinical Liver Disease.2022; 19(2): 68. CrossRef
The association between rs1260326 with the risk of NAFLD and the mediation effect of triglyceride on NAFLD in the elderly Chinese Han population Fan Yuan, Zhan Gu, Yan Bi, Ruixue Yuan, Weibo Niu, Decheng Ren, Lei Zhang, Guang He, Bao-Cheng Liu Aging.2022; 14(6): 2736. CrossRef
Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease (FLD) Laura Valenzuela-Vallejo, Christos S. Mantzoros Metabolism.2022; 134: 155246. CrossRef
Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease Raghu Ramanathan, Ahmad Hassan Ali, Jamal A. Ibdah International Journal of Molecular Sciences.2022; 23(13): 7280. CrossRef
African genetic ancestry is associated with lower frequency of PNPLA3 G allele in non-alcoholic fatty liver in an admixed population Lourianne Nascimento Cavalcante, Jun Porto, Daniel Mazo, Adhemar Longatto-Filho, José Tadeu Stefano, Andre Castro Lyra, Flair Jose Carrilho, Rui Manuel Reis, Venâncio A.F. Alves, Arun J. Sanyal, Claudia P Oliveira Annals of Hepatology.2022; 27(6): 100728. CrossRef
A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation Marijana Vujkovic, Shweta Ramdas, Kim M. Lorenz, Xiuqing Guo, Rebecca Darlay, Heather J. Cordell, Jing He, Yevgeniy Gindin, Chuhan Chung, Robert P. Myers, Carolin V. Schneider, Joseph Park, Kyung Min Lee, Marina Serper, Rotonya M. Carr, David E. Kaplan, M Nature Genetics.2022; 54(6): 761. CrossRef
The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity Magdalena Rausch, Sophia L. Samodelov, Michele Visentin, Gerd A. Kullak-Ublick International Journal of Molecular Sciences.2022; 23(22): 13967. CrossRef
Multifaceted Clinical Research on Obesity-related Disease Prevention Focusing on the DsbA-L Gene Kentaro Oniki YAKUGAKU ZASSHI.2022; 142(11): 1177. CrossRef
Non-alcoholic fatty liver disease (NAFLD) and mental illness: Mechanisms linking mood, metabolism and medicines Anwesha Gangopadhyay, Radwa Ibrahim, Karli Theberge, Meghan May, Karen L. Houseknecht Frontiers in Neuroscience.2022;[Epub] CrossRef
Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MAFLD Paradigm Damien Chua, Zun Siong Low, Guo Xiang Cheam, Aik Seng Ng, Nguan Soon Tan International Journal of Molecular Sciences.2022; 23(23): 14762. CrossRef
Race and Ethnicity in Non-Alcoholic Fatty Liver Disease (NAFLD): A Narrative Review Kiarash Riazi, Mark G. Swain, Stephen E. Congly, Gilaad G. Kaplan, Abdel-Aziz Shaheen Nutrients.2022; 14(21): 4556. CrossRef
Comprehensive analysis of the translatome reveals the relationship between the translational and transcriptional control in high fat diet-induced liver steatosis Zupeng Luo, Hailong Hu, Siqi Liu, Zhiwang Zhang, Yixing Li, Lei Zhou RNA Biology.2021; 18(6): 863. CrossRef
The gut mycobiome: a novel player in chronic liver diseases Lu Jiang, Peter Stärkel, Jian-Gao Fan, Derrick Eugene Fouts, Petra Bacher, Bernd Schnabl Journal of Gastroenterology.2021; 56(1): 1. CrossRef
Flavin Adenine Dinucleotide Depletion Caused by electron transfer flavoprotein subunit alpha Haploinsufficiency Leads to Hepatic Steatosis and Injury in Zebrafish Ki‐Hoon Park, Monika Gooz, Zhi‐Wei Ye, Jie Zhang, Gyda C. Beeson, Don C. Rockey, Seok‐Hyung Kim Hepatology Communications.2021; 5(6): 976. CrossRef
Defining NASH from a Multi-Omics Systems Biology Perspective Lili Niu, Karolina Sulek, Catherine G. Vasilopoulou, Alberto Santos, Nicolai J. Wewer Albrechtsen, Simon Rasmussen, Florian Meier, Matthias Mann Journal of Clinical Medicine.2021; 10(20): 4673. CrossRef
Changes in liver steatosis in HIV-positive women are associated with the BMI, but not with biomarkers Rafael Fernandez-Botran, Michael W. Plankey, Deanna Ware, José Bordon Cytokine.2021; 144: 155573. CrossRef
Human Genetics to Identify Therapeutic Targets for NAFLD: Challenges and Opportunities Xiaomi Du, Natalie DeForest, Amit R. Majithia Frontiers in Endocrinology.2021;[Epub] CrossRef
Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort Yi-Wen Ting, Amanda Shen-Yee Kong, Shamsul Mohd Zain, Wah-Kheong Chan, Hwa-Li Tan, Zahurin Mohamed, Yuh-Fen Pung, Rosmawati Mohamed Clinical and Molecular Hepatology.2021; 27(3): 486. CrossRef
Genetic risk scores and personalization of care in fatty liver disease Cristiana Bianco, Federica Tavaglione, Stefano Romeo, Luca Valenti Current Opinion in Pharmacology.2021; 61: 6. CrossRef
Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients David Sooik Kim, Soo Young Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Kwang-Hyub Han, Yu Rim Lee, Won Young Tak, Young Oh Kweon, Inkyung Jung, Minkyung Han, Eun Hwa Kim, Sang Hoon Ahn, Seung Up Kim Journal of Korean Medical Science.2021;[Epub] CrossRef
Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease Taekyeong Yoo, Sae Kyung Joo, Hyo Jung Kim, Hyun Young Kim, Hyungtai Sim, Jieun Lee, Hee-Hoon Kim, Sunhee Jung, Youngha Lee, Oveis Jamialahmadi, Stefano Romeo, Won-Il Jeong, Geum-Sook Hwang, Keon Wook Kang, Jae Woo Kim, Won Kim, Murim Choi Journal of Hepatology.2021; 75(3): 514. CrossRef
The effects of guluronic acid (G2013), a new emerging treatment, on inflammatory factors in nonalcoholic steatohepatitis patients under in vitro conditions Safa Tahmasebi, Hassan Neishaboori, Davood Jafari, Elham Faghihzadeh, Abdolreza Esmaeilzadeh, Abbas Mirshafiey Immunopharmacology and Immunotoxicology.2021; 43(5): 562. CrossRef
Contribution of Metabolomics to the Understanding of NAFLD and NASH Syndromes: A Systematic Review Cristina Piras, Antonio Noto, Luciano Ibba, Martino Deidda, Vassilios Fanos, Sandro Muntoni, Vera Piera Leoni, Luigi Atzori Metabolites.2021; 11(10): 694. CrossRef
Sirtuin3 rs28365927 functional variant confers to the high risk of non-alcoholic fatty liver disease in Chinese Han population Li-jie Chen, Jing Guo, Song-xia Zhang, Ying Xu, Qing Zhao, Wei Zhang, Jian Xiao, Yao Chen Lipids in Health and Disease.2021;[Epub] CrossRef
Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases João V. S. Guerra, Marieli M. G. Dias, Anna J. V. C. Brilhante, Maiara F. Terra, Marta García-Arévalo, Ana Carolina M. Figueira Nutrients.2021; 13(8): 2830. CrossRef
Lipid nanoparticle formulations for targeting leukocytes with therapeutic RNA in liver fibrosis Matthias Bartneck Advanced Drug Delivery Reviews.2021; 173: 70. CrossRef
Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD) Madhangi Parameswaran, Hamzah A Hasan, Jafor Sadeque, Sharan Jhaveri, Chaithanya Avanthika, Abimbola E Arisoyin, Maulik B Dhanani, Swaroopa M Rath Cureus.2021;[Epub] CrossRef
Racial differences in prevalence and severity of non-alcoholic fatty liver disease Maurizio Bonacini, Farah Kassamali, Swathi Kari, Nieves Lopez Barrera, Mohamed Kohla World Journal of Hepatology.2021; 13(7): 763. CrossRef
Weight change and resolution of fatty liver in normal weight individuals with nonalcoholic fatty liver disease Dong Hyun Sinn, Danbee Kang, Soo Jin Cho, Seung Woon Paik, Eliseo Guallar, Juhee Cho, Geum-Youn Gwak European Journal of Gastroenterology & Hepatology.2021; 33(1S): e529. CrossRef
Non‐alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study Dong Hyun Sinn, Danbee Kang, Yoosoo Chang, Seungho Ryu, Soo Jin Cho, Seung Woon Paik, Young Bin Song, Roberto Pastor‐Barriuso, Eliseo Guallar, Juhee Cho, Geum‐Youn Gwak Journal of Gastroenterology and Hepatology.2020; 35(5): 833. CrossRef
Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology Mohammed Eslam, Jacob George Nature Reviews Gastroenterology & Hepatology.2020; 17(1): 40. CrossRef
Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study Jeong-Ju Yoo, Yang Jae Yoo, Woo Ram Moon, Seung Up Kim, Soung Won Jeong, Ha Na Park, Min Gyu Park, Jae Young Jang, Su Yeon Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Sang Gyune Kim, Young Seok Kim, Ji Hoon Kim, Jong The Korean Journal of Internal Medicine.2020; 35(6): 1346. CrossRef
Fructose-mediated effects on gene expression and epigenetic mechanisms associated with NAFLD pathogenesis Johanna K. DiStefano Cellular and Molecular Life Sciences.2020; 77(11): 2079. CrossRef
Evolution of NAFLD and Its Management Manpreet S. Mundi, Saketh Velapati, Janki Patel, Todd A. Kellogg, Barham K. Abu Dayyeh, Ryan T. Hurt Nutrition in Clinical Practice.2020; 35(1): 72. CrossRef
Liver involvement in patients with Gaucher disease types I and III Rodrigo Tzovenos Starosta, Filippo Pinto e Vairo, Alícia Dorneles Dornelles, Suélen Porto Basgalupp, Marina Siebert, Maria Lúcia Alves Pedroso, Carlos Thadeu Schmidt Cerski, Mário Reis Álvares-da-Silva, Ida Vanessa Doederlein Schwartz Molecular Genetics and Metabolism Reports.2020; 22: 100564. CrossRef
NETGE-PLUS: Standard and Network-Based Gene Enrichment Analysis in Human and Model Organisms Samuele Bovo, Pier Luigi Martelli, Pietro Di Lena, Rita Casadio Journal of Proteome Research.2020; 19(7): 2873. CrossRef
Complications, morbidity and mortality of nonalcoholic fatty liver disease Alessandro Mantovani, Eleonora Scorletti, Antonella Mosca, Anna Alisi, Christopher D. Byrne, Giovanni Targher Metabolism.2020; 111: 154170. CrossRef
Genetic Risk for Hepatic Fat among an Ethnically Diverse Cohort of Youth: The Exploring Perinatal Outcomes among Children Study Maggie A. Stanislawski, Jessica Shaw, Elizabeth Litkowski, Ethan M. Lange, Wei Perng, Dana Dabelea, Leslie A. Lange The Journal of Pediatrics.2020; 220: 146. CrossRef
Patatin‐Like Phospholipase Domain‐Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population Aynur Unalp‐Arida, Constance E. Ruhl Hepatology.2020; 71(3): 820. CrossRef
Does limited expression of toll-like receptor 9 actually contribute to T cell activation and liver damage in nonalcoholic steatohepatitis? Hyuk Soo Eun Clinical and Molecular Hepatology.2020; 26(2): 236. CrossRef
MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease Mohammed Eslam, Arun J. Sanyal, Jacob George, Arun Sanyal, Brent Neuschwander-Tetri, Claudio Tiribelli, David E. Kleiner, Elizabeth Brunt, Elisabetta Bugianesi, Hannele Yki-Järvinen, Henning Grønbæk, Helena Cortez-Pinto, Jacob George, Jiangao Fan, Luca Va Gastroenterology.2020; 158(7): 1999. CrossRef
Human Liver Spheroids as a Model to Study Aetiology and Treatment of Hepatic Fibrosis Tracey Hurrell, Vlasia Kastrinou-Lampou, Achilleas Fardellas, Delilah F. G. Hendriks, Åsa Nordling, Inger Johansson, Audrey Baze, Céline Parmentier, Lysiane Richert, Magnus Ingelman-Sundberg Cells.2020; 9(4): 964. CrossRef
Genome‐Wide Association Study of Lean Nonalcoholic Fatty Liver Disease Suggests Human Leukocyte Antigen as a Novel Candidate Locus Ken Yoshida, Kazuha Yokota, Yukinobu Kutsuwada, Kazuhiro Nakayama, Kazuhisa Watanabe, Ayumi Matsumoto, Hiroshi Miyashita, Seik‐soon Khor, Katsushi Tokunaga, Yosuke Kawai, Masao Nagasaki, Sadahiko Iwamoto Hepatology Communications.2020; 4(8): 1124. CrossRef
Genome‐Wide Association Study of Liver Fat: The Multiethnic Cohort Adiposity Phenotype Study S. Lani Park, Yuqing Li, Xin Sheng, Victor Hom, Lucy Xia, Kechen Zhao, Loreall Pooler, V. Wendy Setiawan, Unhee Lim, Kristine R. Monroe, Lynne R. Wilkens, Bruce S. Kristal, Johanna W. Lampe, Meredith Hullar, John Shepherd, Lenora L. M. Loo, Thomas Ernst, Hepatology Communications.2020; 4(8): 1112. CrossRef
Non-alcoholic fatty liver disease in inflammatory bowel disease patients Katerina Karaivazoglou, Christos Konstantakis, Evanthia Tourkochristou, Stelios F. Assimakopoulos, Christos Triantos European Journal of Gastroenterology & Hepatology.2020; 32(8): 903. CrossRef
Insights Into Extracellular Vesicles as Biomarker of NAFLD Pathogenesis Irma Garcia-Martinez, Rosa Alen, Patricia Rada, Angela M. Valverde Frontiers in Medicine.2020;[Epub] CrossRef
Triose Kinase Controls the Lipogenic Potential of Fructose and Dietary Tolerance Lei Liu, Tian Li, Yilie Liao, Yalong Wang, Yang Gao, Haikun Hu, Haipeng Huang, Fang Wu, Ye-Guang Chen, Shuhua Xu, Suneng Fu Cell Metabolism.2020; 32(4): 605. CrossRef
Noncoding RNAs in Nonalcoholic Fatty Liver Disease: Potential Diagnosis and Prognosis Biomarkers Olfa Khalifa, Khaoula Errafii, Nayla S. Al-Akl, Abdelilah Arredouani Disease Markers.2020; 2020: 1. CrossRef
Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatic Cytochrome P450 (CYP) Enzymes Rohitash Jamwal, Benjamin J. Barlock Pharmaceuticals.2020; 13(9): 222. CrossRef
Non‐alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management Tony (Dazhong) Huang, Jason Behary, Amany Zekry Internal Medicine Journal.2020; 50(9): 1038. CrossRef
Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology Silvia Sookoian, Carlos J. Pirola Clinical and Molecular Hepatology.2020; 26(4): 461. CrossRef
The association of genetic polymorphisms with nonalcoholic fatty liver disease in a longitudinal study Goh Eun Chung, Eunsoon Shin, Min-Sun Kwak, Jong In Yang, Jong-Eun Lee, Eun Kyung Choe, Jeong Yoon Yim BMC Gastroenterology.2020;[Epub] CrossRef
Diversity in NAFLD: A Review of Manifestations of Nonalcoholic Fatty Liver Disease in Different Ethnicities Globally Ma Ai Thanda Han, Qi Yu, Zaid Tafesh, Nikolaos Pyrsopoulos Journal of Clinical and Translational Hepatology.2020; 000(000): 1. CrossRef
Lifestyle and silymarin: a fight against liver damage in NAFLD associated - prediabetic disease Cosimo Colletta, Alessandro Colletta, Giuseppe Placentino Journal of Diabetes & Metabolic Disorders.2020; 19(2): 883. CrossRef
Are Probiotics Effective in Targeting Alcoholic Liver Diseases? Meegun Hong, Dae Hee Han, Jitaek Hong, Dong Joon Kim, Ki Tae Suk Probiotics and Antimicrobial Proteins.2019; 11(2): 335. CrossRef
Clinical and metabolic characterization of obese subjects without non-alcoholic fatty liver: A targeted metabolomics approach A. Feldman, S.K. Eder, T.K. Felder, B. Paulweber, S. Zandanell, L. Stechemesser, M. Schranz, G. Strebinger, U. Huber-Schönauer, D. Niederseer, W. Patsch, D. Weghuber, J. Tevini, C. Datz, E. Aigner Diabetes & Metabolism.2019; 45(2): 132. CrossRef
Molecular pathways of nonalcoholic fatty liver disease development and progression Fernando Bessone, María Valeria Razori, Marcelo G. Roma Cellular and Molecular Life Sciences.2019; 76(1): 99. CrossRef
Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir David Sooik Kim, Mi Young Jeon, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim Clinical and Molecular Hepatology.2019; 25(3): 283. CrossRef
Genetics Meets Therapy? Exome‐wide Association Study Reveals a Loss‐of‐Function Variant in 17‐Beta‐Hydroxysteroid Dehydrogenase 13 That Protects Patients From Liver Damage and Nonalcoholic Fatty Liver Disease Progression Silvia Sookoian, Marco Arrese, Carlos J. Pirola Hepatology.2019; 69(2): 907. CrossRef
Homeostasis of Glucose and Lipid in Non-Alcoholic Fatty Liver Disease Hsu-Wen Chao, Shi-Wei Chao, Heng Lin, Hui-Chen Ku, Ching-Feng Cheng International Journal of Molecular Sciences.2019; 20(2): 298. CrossRef
A Multifaceted Approach regarding the Association of the DsbA-L Gene with the Risk of Obesity-related Diseases Based on Clinical Pharmacogenetics Kentaro Oniki, Junji Saruwatari YAKUGAKU ZASSHI.2019; 139(1): 53. CrossRef
Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease Carlos J. Pirola, Martin Garaycoechea, Diego Flichman, Marco Arrese, Julio San Martino, Carla Gazzi, Gustavo O. Castaño, Silvia Sookoian Journal of Lipid Research.2019; 60(1): 176. CrossRef
Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease Ki Tae Suk, Dong Joon Kim Expert Review of Gastroenterology & Hepatology.2019; 13(3): 193. CrossRef
An integrative systems genetic analysis of mammalian lipid metabolism Benjamin L. Parker, Anna C. Calkin, Marcus M. Seldin, Michael F. Keating, Elizabeth J. Tarling, Pengyi Yang, Sarah C. Moody, Yingying Liu, Eser J. Zerenturk, Elise J. Needham, Matthew L. Miller, Bethan L. Clifford, Pauline Morand, Matthew J. Watt, Ruth C. Nature.2019; 567(7747): 187. CrossRef
Obesity genetics and cardiometabolic health: Potential for risk prediction Dharambir K. Sanghera, Cynthia Bejar, Sonali Sharma, Rajeev Gupta, Piers R. Blackett Diabetes, Obesity and Metabolism.2019; 21(5): 1088. CrossRef
Combined effects of ambient particulate matter exposure and a high-fat diet on oxidative stress and steatohepatitis in mice Shibin Ding, Chunyan Yuan, Bingjie Si, Mengruo Wang, Shuyan Da, Lanxin Bai, Weidong Wu, Qinghua Sun PLOS ONE.2019; 14(3): e0214680. CrossRef
Dysregulation of the Splicing Machinery Is Associated to the Development of Nonalcoholic Fatty Liver Disease Mercedes del Río-Moreno, Emilia Alors-Pérez, Sandra González-Rubio, Gustavo Ferrín, Oscar Reyes, Manuel Rodríguez-Perálvarez, Marina E Sánchez-Frías, Rafael Sánchez-Sánchez, Sebastián Ventura, José López-Miranda, Rhonda D Kineman, Manuel de la Mata, Justo The Journal of Clinical Endocrinology & Metabolism.2019; 104(8): 3389. CrossRef
GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE Network Bahram Namjou, Todd Lingren, Yongbo Huang, Sreeja Parameswaran, Beth L. Cobb, Ian B. Stanaway, John J. Connolly, Frank D. Mentch, Barbara Benoit, Xinnan Niu, Wei-Qi Wei, Robert J. Carroll, Jennifer A. Pacheco, Isaac T. W. Harley, Senad Divanovic, David S. BMC Medicine.2019;[Epub] CrossRef
TRIB1 rs17321515 gene polymorphism increases the risk of coronary heart disease in general population and non-alcoholic fatty liver disease patients in Chinese Han population Qun Liu, Shou-Sheng Liu, Zhen-Zhen Zhao, Ben-Tian Zhao, Shui-Xian Du, Wen-Wen Jin, Yong-Ning Xin Lipids in Health and Disease.2019;[Epub] CrossRef
Effect of weight reduction on histological activity and fibrosis of lean nonalcoholic steatohepatitis patient Shahinul Alam, Mohammad Jahid Hasan, Md. Abdullah Saeed Khan, Mahabubul Alam, Nazmul Hasan Journal of Translational Internal Medicine.2019; 7(3): 106. CrossRef
Lifestyle and Food Habits Impact on Chronic Diseases: Roles of PPARs Michele d’Angelo, Vanessa Castelli, Maria Grazia Tupone, Mariano Catanesi, Andrea Antonosante, Reyes Dominguez-Benot, Rodolfo Ippoliti, Anna Maria Cimini, Elisabetta Benedetti International Journal of Molecular Sciences.2019; 20(21): 5422. CrossRef
Network Modeling Approaches and Applications to Unravelling Non-Alcoholic Fatty Liver Disease Montgomery Blencowe, Tilan Karunanayake, Julian Wier, Neil Hsu, Xia Yang Genes.2019; 10(12): 966. CrossRef
Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations Ramesh Kumar, Rajeev Nayan Priyadarshi, Utpal Anand Journal of Clinical and Translational Hepatology.2019; X(X): 1. CrossRef
Systematic review with meta‐analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease S. Sookoian, C. J. Pirola Alimentary Pharmacology & Therapeutics.2018; 47(1): 16. CrossRef
Sex differences between parental pregnancy characteristics and nonalcoholic fatty liver disease in adolescents Oyekoya T. Ayonrinde, Leon A. Adams, Trevor A. Mori, Lawrence J. Beilin, Nicholas de Klerk, Craig E. Pennell, Scott White, John K Olynyk Hepatology.2018; 67(1): 108. CrossRef
Endocrine Disruptors and Developmental Origins of Nonalcoholic Fatty Liver Disease Lindsey S Treviño, Tiffany A Katz Endocrinology.2018; 159(1): 20. CrossRef
Lean NAFLD: A not so benign condition? Lisa B. VanWagner, Matthew J. Armstrong Hepatology Communications.2018; 2(1): 5. CrossRef
Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies Julia Wattacheril, Danny Issa, Arun Sanyal Annual Review of Pharmacology and Toxicology.2018; 58(1): 649. CrossRef
Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy Alessia Di Costanzo, Francesca Belardinilli, Diego Bailetti, Marialuisa Sponziello, Laura D’Erasmo, Licia Polimeni, Francesco Baratta, Daniele Pastori, Fabrizio Ceci, Anna Montali, Gabriella Girelli, Bruna De Masi, Antonio Angeloni, Giuseppe Giannini, Mar Scientific Reports.2018;[Epub] CrossRef
Combining Genetic Variants to Improve Risk Prediction for NAFLD and Its Progression to Cirrhosis: A Proof of Concept Study Umberto Vespasiani-Gentilucci, Chiara Dell’Unto, Antonio De Vincentis, Andrea Baiocchini, Marco Delle Monache, Roberto Cecere, Adriano Maria Pellicelli, Valerio Giannelli, Simone Carotti, Giovanni Galati, Paolo Gallo, Francesco Valentini, Franca Del Nonno Canadian Journal of Gastroenterology and Hepatology.2018; 2018: 1. CrossRef
Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica Rocío Aller, Conrado Fernández-Rodríguez, Oreste lo Iacono, Rafael Bañares, Javier Abad, José Antonio Carrión, Carmelo García-Monzón, Joan Caballería, Marina Berenguer, Manuel Rodríguez-Perálvarez, José López Miranda, Eduardo Vilar-Gómez, Javier Crespo, M Gastroenterología y Hepatología.2018; 41(5): 328. CrossRef
NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk? Subada Soti, Kathleen E. Corey, Jordan E. Lake, Kristine M. Erlandson Current HIV/AIDS Reports.2018; 15(3): 212. CrossRef
Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity Carlos J Pirola, Silvia Sookoian World Journal of Gastroenterology.2018; 24(15): 1601. CrossRef
The gut–liver axis and the intersection with the microbiome Anupriya Tripathi, Justine Debelius, David A. Brenner, Michael Karin, Rohit Loomba, Bernd Schnabl, Rob Knight Nature Reviews Gastroenterology & Hepatology.2018; 15(7): 397. CrossRef
Nonalcoholic Steatohepatitis Michael H. Schild, Cynthia D. Guy Surgical Pathology Clinics.2018; 11(2): 267. CrossRef
Dietary carbohydrates and fatty liver disease Sally Chiu, Kathleen Mulligan, Jean-Marc Schwarz Current Opinion in Clinical Nutrition & Metabolic Care.2018; 21(4): 277. CrossRef
Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline Rocío Aller, Conrado Fernández-Rodríguez, Oreste lo Iacono, Rafael Bañares, Javier Abad, José Antonio Carrión, Carmelo García-Monzón, Joan Caballería, Marina Berenguer, Manuel Rodríguez-Perálvarez, José López Miranda, Eduardo Vilar-Gómez, Javier Crespo, M Gastroenterología y Hepatología (English Edition).2018; 41(5): 328. CrossRef
Integrated transcriptomics and metabolomics reveal signatures of lipid metabolism dysregulation in HepaRG liver cells exposed to PCB 126 Robin Mesnage, Martina Biserni, Sucharitha Balu, Clément Frainay, Nathalie Poupin, Fabien Jourdan, Eva Wozniak, Theodoros Xenakis, Charles A. Mein, Michael N. Antoniou Archives of Toxicology.2018; 92(8): 2533. CrossRef
Mechanisms of NAFLD development and therapeutic strategies Scott L. Friedman, Brent A. Neuschwander-Tetri, Mary Rinella, Arun J. Sanyal Nature Medicine.2018; 24(7): 908. CrossRef
The Role of Long Non-Coding RNAs (lncRNAs) in the Development and Progression of Fibrosis Associated with Nonalcoholic Fatty Liver Disease (NAFLD) Amanda Hanson, Danielle Wilhelmsen, Johanna K. DiStefano Non-Coding RNA.2018; 4(3): 18. CrossRef
Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis Brett R Loman, Diego Hernández-Saavedra, Ruopeng An, R Scott Rector Nutrition Reviews.2018; 76(11): 822. CrossRef
Science, serendipity, and the single degree Helen H. Hobbs Journal of Clinical Investigation.2018; 128(10): 4218. CrossRef
Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics Min Seok Cho, Sang Yeol Kim, Ki Tae Suk, Byung-Yong Kim Journal of Microbiology.2018; 56(12): 855. CrossRef
Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables Umberto Vespasiani-Gentilucci, Paolo Gallo, Chiara Dell’Unto, Mara Volpentesta, Raffaele Antonelli-Incalzi, Antonio Picardi World Journal of Gastroenterology.2018; 24(43): 4835. CrossRef
Nonalcoholic Fatty Liver Disease Progresses into Severe NASH when Physiological Mechanisms of Tissue Homeostasis Collapse Silvia Sookoian, Carlos J. Pirola Annals of Hepatology.2018; 17(2): 182. CrossRef
A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease Paola Dongiovanni, Luca Valenti International Journal of Molecular Sciences.2017; 18(7): 1534. CrossRef
Hígado graso no alcohólico: una pandemia poco conocida Salvador Augustin, Isabel Graupera, Juan Caballeria Medicina Clínica.2017; 149(12): 542. CrossRef
Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals Giuseppe Della Pepa, Claudia Vetrani, Gianluca Lombardi, Lutgarda Bozzetto, Giovanni Annuzzi, Angela Rivellese Nutrients.2017; 9(10): 1065. CrossRef
What Is the Optimal Dietary Composition for NAFLD? Elena S. George, Audrey C. Tierney, Katrina L. Campbell, Graeme A. Macdonald, Ingrid J. Hickman Current Hepatology Reports.2017; 16(4): 346. CrossRef
Non-alcoholic fatty liver disease: A poorly known pandemic Salvador Augustin, Isabel Graupera, Juan Caballeria Medicina Clínica (English Edition).2017; 149(12): 542. CrossRef
First
Prev
